The feds have taken another drug dealer off the streets. This one sold more than $7 million worth of unapproved foreign cancer drugs from Turkey, Pakistan, India, and elsewhere to oncologists who were administering them to their patients.
Over their lifetimes, Baby Boomers have pumped product sales in one market after another, starting with diapers. Now, aging Boomers are set to influence another business altogether: cancer drugs.
Friday, the agency dubbed Arzerra a "breakthrough therapy," a coveted designation that puts the leukemia drug into the fast lane for first-line use. And today, the FDA put GSK's new melanoma duo, Tafinlar and Mekinist, on its priority review track as a combination cocktail.
Japanese regulators have cleared Bayer's cancer drug Stivarga for a new use, against gastrointestinal stromal tumors. It's just the latest victory for the fast-tracked drug, developed with U.S.-based Onyx Pharmaceuticals.
If good fences make good neighbors, then doctors' offices and pharma reps are getting more neighborly all the time. Some 45% of prescribers restrict sales reps' access these days, according to an annual report from ZS Associates.
Cancer drugs are hot. With new targeted therapies coming online--and immunotherapies the talk of this year's ASCO meeting--oncologists are getting new treatments for their tool chests, and drugmakers are adding lucrative products to their cash boxes.
For more than a year, U.S. authorities have been tightening a noose around Internet pharmacy company Canada Drugs, which reportedly was the source of counterfeit Avastin shipped last year to doctors.
Pfizer has run into the U.K. watchdog wall of resistance to targeted cancer drugs with its renal cancer treatment Inlyta.
Taiwan's TOT Biopharm has opened in mainland China the first phase of what it says is a $100 million plant for developing and manufacturing cancer drugs for the global market.
Cipla is roiling the waters in India again. Six months after slashing the prices on three cancer drugs--including a knockoff of Bayer's still-on-patent Nexavar--the company has issued another round of hefty price cuts.